logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Farmaindustria bets on digitization to consolidate Spain in drug trials

In the workshop “Digital challenges in the management of clinical trials”, organized by Farmaindustria, its attendees have shown their commitment to digitization to help Spain consolidate its international position in clinical drug research.

Spain is an international reference for conducting clinical trials of new drugs, as shown in the research effort deployed to deal with the current coronavirus pandemic: it is the first European country and the fourth in the world in number of tests against the virus. “Precisely, the experience accumulated during these months has led to the application of digitization to these processes having undergone a strong acceleration”, highlights the employers of the national pharmaceutical industry.

“The impossibility of traveling to hospitals during the pandemic led to the activation of new processes, such as the electronic signature of research contracts, visits to start the trials virtually or the possibility of remote monitoring of the trials verifying the source data, together with the sending of the medication to the home of the participants in a trial ”, explained Amelia Martín, who is responsible for the Platform of Innovative Medicines of Farmaindustria.

“Many of these processes have come to stay and others will be incorporated as a complement or an alternative in many hospitals. Everything that we can implement that avoids the displacement of patients with guarantees from the point of view of the confidentiality of their data will be a great advance both now and later ”, added Amelia Martín.

Efficiency in testing
“With these advances in digitization, the fundamental thing at this time is that all the agents involved in this field – healthcare professionals, researchers and managers of hospitals and public and private centers, together with pharmaceutical companies – can be trained in these new tools and digital skills with the aim of increasing efficiency in the tests ”, highlighted this spokesperson for said employer’s association.

For this reason, this workshop was held online, in which more than 340 professionals from hospitals and research centers participated, as well as from the pharmaceutical industry, all of them adhered to the BEST Project, a program promoted by Farmaindustria to make Spain “a country of excellence in research and improve in key areas”, such as start-up times and patient recruitment, one of the aspects where there is a greater capacity for progression.

In this webinar, other issues were discussed, such as electronic informed consent, an area in which the need to create an interdisciplinary working group among different actors – regulatory agencies, promoters, researchers, CEIm members and patients – was highlighted in order to “advance in an area of ??the future that, without a doubt, has to bring added value to patients ”.

Related entries

24 September, 2025

Advanced therapies in lymphoma: six years of CAR-T that have changed patients’ lives


Leer más
17 September, 2025

The Community of Madrid aspires to become the “Silicon Valley” of the pharmaceutical sector.


Leer más
16 September, 2025

Farmaindustria welcomes the announcement by the Spanish Agency for Medicines and Health Products (AEMPS) to expand the accelerated assessment of early-stage clinical trials, as this strengthens the Spanish biomedical research ecosystem.


Leer más

Recent Posts

  • Advanced therapies in lymphoma: six years of CAR-T that have changed patients’ lives
  • The Community of Madrid aspires to become the “Silicon Valley” of the pharmaceutical sector.
  • Farmaindustria welcomes the announcement by the Spanish Agency for Medicines and Health Products (AEMPS) to expand the accelerated assessment of early-stage clinical trials, as this strengthens the Spanish biomedical research ecosystem.
  • Australia’s recipe for strengthening medical research capacity and leading the way into the next decade
  • Study identifies proteins involved in the efficacy of immunotherapy against blood cancer

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.